GZMB and cancer: Granzyme B is also a molecule that correlates with the anti-tumor activity of cytotoxic T cells, as PET (Positron Emission Tomography) measurements have shown that it may be used as an early biomarker of therapeutic response in cancer immunotherapy such as anti-PD-1 therapy [23].